Link Among Obesity, Estrogen Status, and Breast Cancer Mortality

TOP - Daily - Breast Cancer

Maintaining a healthy body weight is important for all patients. But, this is especially true for women with a breast cancer diagnosis, as an analysis of the California Teachers Study has shown a correlation between breast cancer deaths and body mass index (BMI).

Obesity (defined as BMI ≥30 kg/m²) increased a woman’s risk of dying of their breast cancer by 69%, compared with women with a BMI <25. For patients who were overweight at 18 years of age (defined as BMI 25-29), a similar increased risk in breast cancer mortality was detected.

Additionally, the association between obesity and breast cancer mortality is greatest among obese women who are diagnosed with estrogen receptor (ER)-positive cancer. According to the retrospective data analysis, ER-positive, obese women participating in the study had a 64% increased risk of death from breast cancer (compared with those with a BMI <25).

In light of these statistics, what are some ways medical professionals can continue to encourage healthy body weight among patients? What healthy eating and exercise strategies have you seen have a positive impact on patient lifestyle(s)? Share your suggestions and ideas in the comments section below.

Related Items
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Efficacy Outcomes of Platinum-Based Chemotherapy in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Last modified: April 15, 2021